PURPOSE: The purpose of this study was to establish the mutation spectrum of an Usher type I cohort of 61 patients from France and to describe a diagnostic strategy, including a strategy for estimating the pathogenicity of sequence changes. METHODS: To optimize the identification of Usher (USH)-causative mutations, taking into account the genetic heterogeneity, preliminary haplotyping at the five USH1 loci was performed to prioritize the gene to be sequenced, as previously described. Coding exons and flanking intronic sequences were sequenced and, where necessary, semiquantitative PCR and multiplex ligation-dependent probe amplification (MLPA) were performed to detect large genomic rearrangements. RESULTS: Four years ' experience confirms that the chosen approach provides an efficient diagnostic service. Sixty-one patients showed an abnormal genotype in one of the five USH1 genes. Genetic heterogeneity was confirmed, and, although MYO7A remains the major gene, involvement of other genes is considerable. Distribution of missense, splicing, premature termination codons (PTCs; due to point substitution and small deletions/ or insertions), and large genomic alterations was determined among the USH genes and clearly highlights the need to pay special attention to the diagnostic approach and interpretation, depending on the mutated gene. CONCLUSIONS: Over the 4 years of a diagnostic service offering USH1 patient testing, pathogenic genotypes were identified in most cases (>90%). The complexity and heterogeneity of mutations reinforces the need for a comprehensive approach. Because 32% of the mutations are newly described, the results show that a screening strategy based on known mutations would have solved less than 55% of the cases.
PURPOSE: The purpose of this study was to establish the mutation spectrum of an Usher type I cohort of 61 patients from France and to describe a diagnostic strategy, including a strategy for estimating the pathogenicity of sequence changes. METHODS: To optimize the identification of Usher (USH)-causative mutations, taking into account the genetic heterogeneity, preliminary haplotyping at the five USH1 loci was performed to prioritize the gene to be sequenced, as previously described. Coding exons and flanking intronic sequences were sequenced and, where necessary, semiquantitative PCR and multiplex ligation-dependent probe amplification (MLPA) were performed to detect large genomic rearrangements. RESULTS: Four years ' experience confirms that the chosen approach provides an efficient diagnostic service. Sixty-one patients showed an abnormal genotype in one of the five USH1 genes. Genetic heterogeneity was confirmed, and, although MYO7A remains the major gene, involvement of other genes is considerable. Distribution of missense, splicing, premature termination codons (PTCs; due to point substitution and small deletions/ or insertions), and large genomic alterations was determined among the USH genes and clearly highlights the need to pay special attention to the diagnostic approach and interpretation, depending on the mutated gene. CONCLUSIONS: Over the 4 years of a diagnostic service offering USH1 patient testing, pathogenic genotypes were identified in most cases (>90%). The complexity and heterogeneity of mutations reinforces the need for a comprehensive approach. Because 32% of the mutations are newly described, the results show that a screening strategy based on known mutations would have solved less than 55% of the cases.
Authors: Mohsin Shahzad; Theru A Sivakumaran; Tanveer A Qaiser; Julie M Schultz; Zawar Hussain; Megan Flanagan; Munir A Bhinder; Diane Kissell; John H Greinwald; Shaheen N Khan; Thomas B Friedman; Kejian Zhang; Saima Riazuddin; Sheikh Riazuddin; Zubair M Ahmed Journal: Otolaryngol Head Neck Surg Date: 2013-06-14 Impact factor: 3.497
Authors: Polona Le Quesne Stabej; Zubin Saihan; Nell Rangesh; Heather B Steele-Stallard; John Ambrose; Alison Coffey; Jenny Emmerson; Elene Haralambous; Yasmin Hughes; Karen P Steel; Linda M Luxon; Andrew R Webster; Maria Bitner-Glindzicz Journal: J Med Genet Date: 2011-12-01 Impact factor: 6.318
Authors: Amal Souissi; Mariem Ben Said; Ikhlas Ben Ayed; Ines Elloumi; Amal Bouzid; Mohamed Ali Mosrati; Mehdi Hasnaoui; Malek Belcadhi; Nabil Idriss; Hassen Kamoun; Nourhene Gharbi; Abdullah A Gibriel; Abdelaziz Tlili; Saber Masmoudi Journal: J Adv Res Date: 2021-01-12 Impact factor: 10.479
Authors: Gema García-García; Thomas Besnard; David Baux; Christel Vaché; Elena Aller; Sue Malcolm; Mireille Claustres; Jose M Millan; Anne-Françoise Roux Journal: Mol Vis Date: 2013-02-13 Impact factor: 2.367
Authors: Heather B Steele-Stallard; Polona Le Quesne Stabej; Eva Lenassi; Linda M Luxon; Mireille Claustres; Anne-Francoise Roux; Andrew R Webster; Maria Bitner-Glindzicz Journal: Orphanet J Rare Dis Date: 2013-08-08 Impact factor: 4.123